210 related articles for article (PubMed ID: 24373858)
21. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression.
Cai H; Li Z; Huang CW; Shahinian AH; Wang H; Park R; Conti PS
Bioconjug Chem; 2010 Aug; 21(8):1417-24. PubMed ID: 20666401
[TBL] [Abstract][Full Text] [Related]
22. New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative.
Halime Z; Frindel M; Camus N; Orain PY; Lacombe M; Bernardeau K; Chérel M; Gestin JF; Faivre-Chauvet A; Tripier R
Org Biomol Chem; 2015 Dec; 13(46):11302-14. PubMed ID: 26419637
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
[TBL] [Abstract][Full Text] [Related]
24. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors.
Wadas TJ; Eiblmaier M; Zheleznyak A; Sherman CD; Ferdani R; Liang K; Achilefu S; Anderson CJ
J Nucl Med; 2008 Nov; 49(11):1819-27. PubMed ID: 18927338
[TBL] [Abstract][Full Text] [Related]
25. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
Luo H; England CG; Graves SA; Sun H; Liu G; Nickles RJ; Cai W
J Nucl Med; 2016 Feb; 57(2):285-90. PubMed ID: 26541778
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
27. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
28.
Pyo A; Yun M; Kim HS; Kim TY; Lee JJ; Kim JY; Lee S; Kwon SY; Bom HS; Kim HS; Kim DY; Min JJ
J Nucl Med; 2018 Feb; 59(2):340-346. PubMed ID: 28916621
[TBL] [Abstract][Full Text] [Related]
29. Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.
Guo Y; Ferdani R; Anderson CJ
Bioconjug Chem; 2012 Jul; 23(7):1470-7. PubMed ID: 22663248
[TBL] [Abstract][Full Text] [Related]
30. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
[TBL] [Abstract][Full Text] [Related]
31. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
32. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
33. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer.
Hwang DW; Ko HY; Lee JH; Kang H; Ryu SH; Song IC; Lee DS; Kim S
J Nucl Med; 2010 Jan; 51(1):98-105. PubMed ID: 20008986
[TBL] [Abstract][Full Text] [Related]
34. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
[TBL] [Abstract][Full Text] [Related]
35. ⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.
Banerjee SR; Pullambhatla M; Foss CA; Nimmagadda S; Ferdani R; Anderson CJ; Mease RC; Pomper MG
J Med Chem; 2014 Mar; 57(6):2657-69. PubMed ID: 24533799
[TBL] [Abstract][Full Text] [Related]
36.
Ocak M; Beaino W; White A; Zeng D; Cai Z; Anderson CJ
Cancer Biother Radiopharm; 2018 Mar; 33(2):74-83. PubMed ID: 29634417
[TBL] [Abstract][Full Text] [Related]
37. Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody.
Dearling JL; Voss SD; Dunning P; Snay E; Fahey F; Smith SV; Huston JS; Meares CF; Treves ST; Packard AB
Nucl Med Biol; 2011 Jan; 38(1):29-38. PubMed ID: 21220127
[TBL] [Abstract][Full Text] [Related]
38. Biological stability evaluation of the α2β1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide.
Huang CW; Li Z; Cai H; Shahinian T; Conti PS
Bioconjug Chem; 2011 Feb; 22(2):256-63. PubMed ID: 21244039
[TBL] [Abstract][Full Text] [Related]
39. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
Persson M; Madsen J; Østergaard S; Jensen MM; Jørgensen JT; Juhl K; Lehmann C; Ploug M; Kjaer A
J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823
[TBL] [Abstract][Full Text] [Related]
40. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
